36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI

• Status: Active, not recruiting
• Trial end date: 2022-07-31

Summary

This study is to observe the efficacy and safety of 36 weeks short-term optimization treatment of glucocorticosteroid in the patients with chronic recurrent drug-induced liver injury (DILI).

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Beijing 302 Hospital
• Treatments: Alprostadil; Glucocorticoids; Glycyrrhizic Acid; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Ursodeoxycholic Acid